Technology | 2018.02.06
Audentes Therapeutics Announces Selection of Optimized Clinical Development Candidate for Pompe Disease Program
SAN FRANCISCO, Feb. 6, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced it has selected an optimized cli...
For more information, please visit
https://www.prnewswire.com/news-releases[...]disease-program-300594605.html
Follow us on
📊 Most Viewed News
- • The complete guide to making your product international - The Nex... (15,542)
- • Colaboração 2.0: Breaking Down the Language Barrier - Business ... (12,034)
- • A Start-Up Bets on Human Translators Over Machines - New York Tim... (11,530)
- • Immigrants 'should learn English' - Politics.co.uk (11,209)
- • How OpenStack gets translated - opensource.com (11,044)
- • easyJet Chooses TransPerfect for Pan-European Translation - Busin... (10,934)
- • Para-Plus Translations Honored by Philadelphia Business Journal .... (10,367)
- • Google Adds Customized Translations for Website Owners - PC Magaz... (10,257)